News Updates

More Articles Back to Article

Efanesoctocog alfa shows effectiveness in hemophilia

Sanofi announced that phase 3 data of efanesoctocog alfa hemophilia A treatment delivered normal to near-normal factor activity levels for the majority of the week with once-weekly dosing, adding that it met primary and key secondary endpoints and provided superior bleeding prevention to prophylaxis treatment. Results of the clinical trial were published in The New England Journal of Medicine. PharmaTimes magazine (UK) (1/31)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!